NovoCure (NVCR) Change in Accured Expenses (2014 - 2026)

NovoCure (NVCR) has reported Change in Accured Expenses for 13 consecutive years, with $2.8 million the latest figure, recorded in Q2 2026.

• Quarterly Change in Accured Expenses fell 52.74% year-over-year to $2.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $30.9 million (up 78.88% YoY) and the FY2025 annual result came in at $19.0 million, down 0.77% from the prior year.
• Change in Accured Expenses improved to $2.8 million in Q2 2026 per NVCR's latest filing, from -$5.1 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for NVCR reached as high as $24.8 million in Q3 2025 and fell as low as -$18.2 million in Q1 2024.
• A 5-year average of $3.9 million and a median of $6.1 million in 2023 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses slumped 463.94% — and 2024, when it soared 716.07%.
• Year by year, Change in Accured Expenses stood at $16.2 million in 2022, then advanced by 16.77% to $18.9 million in 2023, then gained by 7.9% to $20.4 million in 2024, then tumbled by 58.52% to $8.4 million in 2025, then slumped by 66.86% to $2.8 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $2.8 million, -$5.1 million, and $8.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.